Linked Life Data

11571419

Source:http://linkedlifedata.com/resource/pubmed/id/11571419

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-9-25
pubmed:abstractText
As the prevalence of resistant Gram-positive organisms in the critical care unit has increased, so have the associated morbidity and mortality and the cost of their treatment. As a result, more toxic and less active second-line agents and combinations of agents are used, often with limited evidence of clinical benefit. Although widely used, the role of glycopeptides is limited by increasing resistance and poor pharmacokinetics. New agents now in use, such as quinupristin/dalfopristin and Linezolid (Zyvox; Pharmacia & Upjohn, Kalamazoo, MI), show promise, as do diverse agents in development. The future is likely to bring greater therapeutic choice but, inevitably, further resistance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1070-5295
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
232-7
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
New anti-Gram-positive agents.
pubmed:affiliation
Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Hills Road, Cambridge 01223 257035, UK. dave.hamilton1@virgin.net
pubmed:publicationType
Journal Article, Review